Business
BullFrog AI Expands Sales and Marketing Team to Accelerate Commercial Adoption of Clinical Trial Optimization Solutions and bfPREP™ Module
GAITHERSBURG, Md., Sept. 30, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the expansion of its internal sales organization to support accelerated commercialization of the Company’s clinical trial optimization offerings, including its recently lau
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"image","alt":"BullFrog AI Holdings, Inc.","displaySize":"","headline":null,"caption":"BullFrog AI Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/40a6d1d7288dd7624185c5755b024c0e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cckXAhHY1jCBABonzk6CjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/40a6d1d7288dd7624185c5755b024c0e","width":300,"height":73}},"lazy":false},{"type":"text","content":"GAITHERSBURG, Md., Sept. 30, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the expansion of its internal sales organization to support accelerated commercialization of the Company’s clinical trial optimization offerings, including its recently launched bfPREP™ module.","length":546,"tagName":"p"},{"type":"text","content":"The expansion of BullFrog AI’s in-house sales capabilities complements the Company’s recent commercial rollout with Sygnature Discovery, which is focused on selling BullFrog Data Networks™ target selection solutions to global biopharma clients. By strengthening its direct sales organization, BullFrog AI is positioned to accelerate adoption of its trial-focused platforms, including bfPREP, among pharmaceutical and biotechnology companies.","length":441,"tagName":"p"},{"type":"text","content":"“While our collaboration with Sygnature positions BullFrog Data Networks™ as a powerful target discovery solution for global biopharma R&D, the expansion of our sales team strengthens our ability to directly market and deliver bfPREP and clinical trial optimization tools to drug developers worldwide,” said Vin Singh, Founder and CEO of BullFrog AI. “This dual-pronged strategy broadens our commercial reach and ensures we are capturing opportunities across the full drug development lifecycle.”","length":500,"tagName":"p"},{"type":"text","content":"The bfPREP module, originally developed to support BullFrog AI’s collaboration with Eleison Pharmaceuticals, is purpose-built to handle the scale and complexity of diverse c...